GET DAILY SIGNALSHeartBeam (BEAT) Trading Near $0.41 After -90% Drop: Can It Reach the $4.00 Target?
Key Takeaways
- The central $4.00 target is the arithmetic mean of four identifiable analyst price targets — $2.00 from Maxim Group, $4.00 from B. Riley Securities, and $5.00 each from StoneX and Benchmark — across a wide $2.00-to-$5.00 range.
- At the latest price near $0.41, reaching $4.00 requires roughly 875% upside, a very large move by any standard.
- Most of these targets were set in spring and summer 2026, before the stock's sharp decline, and coverage is thin and inconsistent across data providers.
- Supporting factors include an FDA-cleared ambulatory ECG platform, an extended funding runway, and a narrowing quarterly net loss.
- Principal risks are pre-revenue, development-stage execution, recurring shareholder dilution, and the possibility of further target cuts.
- For more on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for a fuller picture.
Analyst Price Targets and Consensus View
Four current, identifiable analyst price targets stand out. The low is $2.00 from Maxim Group, which initiated coverage with a Buy in July 2026. The high is $5.00, held by both StoneX (reiterated Buy in August 2026) and Benchmark (which lowered its target from $8 in May 2026). B. Riley Securities set a $4.00 target in March 2026. The arithmetic mean is $4.00, within a wide $2.00-to-$5.00 range.
The picture is unusually fragmented. H.C. Wainwright lowered its target to $2.50 in May 2026 and then downgraded the stock to Neutral in September 2026, effectively removing its price objective, while D. Boral Capital downgraded to Hold in April 2026. Some aggregators report an average closer to $3.50 based on a different, smaller subset of targets. Because most targets substantially predate the stock's collapse and have not yet caught up, they should be read as indicative rather than precise. Bullish analysts emphasize the long-term remote cardiac monitoring opportunity; cautious voices point to slower commercial traction and dilution. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified price is about $0.41, with a market capitalization near $23 million. Reaching the $4.00 central target would require a gain of roughly 875%, which is a very large move. HeartBeam remains development-stage and loss-making, with negative earnings per share (EPS). Its most recent quarterly results showed a net loss in the low-teens millions of dollars, narrowing modestly year-over-year, and the company completed an equity raise at $0.80 per share in 2026 to extend its funding runway. The 52-week range of $0.355 to $4.00 underscores both the depth of the decline and the fact that the stock has already traded at the target level within the past year.
What Could Support a Move Toward the Target
- Product and regulatory milestones. The company's FDA-cleared, credit-card-sized ECG platform targets a large addressable market for remote and ambulatory cardiac monitoring.
- Funding runway. Recent capital raises have extended the cash runway, supporting continued commercialization efforts.
- Improving losses. A narrowing net loss suggests some operating expense discipline even before meaningful revenue.
- Residual analyst support. Several Buy ratings remain in place, reflecting long-term optimism about the technology.
What Could Prevent the Target From Being Reached
- Pre-revenue execution risk. Commercialization has ramped more slowly than analysts originally modeled, prompting repeated target reductions.
- Dilution. Additional equity raises at low prices have weighed heavily on per-share value and analyst fair-value estimates.
- Funding needs. As a development-stage company, continued cash burn may require further capital.
- Further downgrades. H.C. Wainwright's move to Neutral and D. Boral Capital's Hold rating signal waning conviction, and stale targets could be cut again.
- Micro-cap volatility. Thin coverage and modest liquidity magnify price swings in both directions.
Technical Levels and Market Structure
The technical backdrop is notably weak. The $4.00 central target coincides with the stock's 52-week high, a level that now functions as major resistance and a prior breakdown point. Support sits near the $0.355-to-$0.40 zone around the 52-week low, with psychological levels at $0.50 and $1.00 in between. The long-term trend remains firmly negative, and the stock would need to reclaim progressively higher levels with sustained volume before any credible recovery toward the target could unfold.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for each BEAT report is not always disclosed and can vary. Investors should monitor upcoming quarterly results and guidance, any new or revised funding arrangements, FDA and commercial launch milestones, and analyst target revisions. Given the divergence between the share price and the remaining targets, fresh analyst commentary will be especially informative. From what I see, this is important because the gap between current levels and the targets highlights how much needs to change for a recovery.
Using AI Tools in My Analysis
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like BEAT, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual review.
Final Assessment
The $4.00 central target is the average of four identifiable analyst price targets spanning $2.00 to $5.00, but it reflects a valuation framework established largely before HeartBeam's roughly 90% decline. The required move of about 875% is very large, and the stock's development-stage status, recurring dilution, and already-softening analyst sentiment present serious obstacles. On the other side, an FDA-cleared product, an extended funding runway, and a narrowing loss provide a foundation. Whether the target is reachable depends on tangible commercial traction and funding stability; no outcome is guaranteed, and the wide analyst range signals genuine disagreement about the company's trajectory.
Exploring Tickeron AI Tools
In my own research process, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals for additional perspective on stocks like this one. The platform applies AI to scan market data and highlight potential signals, which can complement traditional analysis when evaluating development-stage companies with thin coverage. It has become a useful part of how I cross-check technical setups and stay updated on momentum shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BEAT in +1.31% Uptrend, growing for three consecutive days on November 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BEAT advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAT as a result. In 78 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for BEAT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
BEAT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BEAT crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.770) is normal, around the industry mean (4.477). P/E Ratio (-0.788) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a wireless medical technology company, which focuses on the delivery of health information
Industry ServicestotheHealthIndustry
Advertisement